THE COMPARISON OF GOOGLE BARD AND CHATGPT USE IN FINANCIAL MARKETS
Sosyal Bilimler Akademi Dergisi · 2023
DOI: 10.38004/sobad.1343515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sosyal Bilimler Akademi Dergisi, 2023. Verfasst von Samet GÜRSOY und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
The main purpose of this study is to investigate the advantages and disadvantages of using ChatGPT and Google Bard in finance. As a method, academic studies and researches done so far were examined. In this direction, the advantages and disadvantages of both methods were tried to be presented in tables. As a result of the study, it was observed that special abilities can be attributed to both artificial intelligence systems, and when compared, it was found that the net advantage would be better understood over time. Because artificial intelligence systems are fed by the feedback of users. However, it has been observed that while ChatGPT works effectively in data analysis and rapid decision making, it may have limitations when it comes to freedom from emotion and bias. Google Bard, on the other hand, has been stated to be effective in risk management and portfolio optimization with its advanced forecasting and analysis capabilities. However, it is common opinion that the use of up-to-date and accurate data is important in both systems and that the factors will affect the performance of the methods.
Zitieren
APA
GÜRSOY, S., & KILIÇ, E. (2023). THE COMPARISON OF GOOGLE BARD AND CHATGPT USE IN FINANCIAL MARKETS. Sosyal Bilimler Akademi Dergisi. https://doi.org/10.38004/sobad.1343515
Vancouver
GÜRSOY S, KILIÇ E. THE COMPARISON OF GOOGLE BARD AND CHATGPT USE IN FINANCIAL MARKETS. Sosyal Bilimler Akademi Dergisi. 2023. doi:10.38004/sobad.1343515
BibTeX
@article{GRSOY2023,
author = {GÜRSOY, Samet and KILIÇ, Ethem},
title = {THE COMPARISON OF GOOGLE BARD AND CHATGPT USE IN FINANCIAL MARKETS},
journal = {Sosyal Bilimler Akademi Dergisi},
year = {2023},
doi = {10.38004/sobad.1343515}
}
EUVIMED